About Biogen

Biogen Inc. (Biogen) is a global biopharmaceutical company. The company focuses on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. The company has a broad portfolio of medicines to treat MS, has introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer’s disease and launched the first approved treatment to target a genetic cause of ALS. Through the company’s 2023 acquisition of Reata, the company markets the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. The company is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. The company supports its drug discovery and development efforts through internal research and development programs and external collaborations. The company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. The company also has collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD. The company has certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; and COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma, as well as has the option to add other anti-CD20 therapies, pursuant to the company’s collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. The company commercializes a portfolio of biosimilars of advanced biologics, including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in the U.S. and certain international markets. The company also has exclusive rights to commercialize TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. The company continues to develop potential biosimilar product SB15, a proposed aflibercept biosimilar referencing EYLEA. In February 2023, the company was exploring strategic options for its biosimilars business. Developments In Key Collaborative Relationships LEQEMBI (lecanemab) The United States In July 2023, the FDA granted traditional approval of LEQEMBI, an anti-amyloid antibody for the treatment of Alzheimer's disease, which was previously granted accelerated approval by the FDA in January 2023. Following the FDA's traditional approval of LEQEMBI, CMS confirmed broader coverage of LEQEMBI. Additionally, in March 2023, Eisai announced that the U.S. Veteran's Health Administration will be providing coverage of LEQEMBI to veterans living with early stages of Alzheimer's disease. Rest of World Key developments related to LEQEMBI (lecanemab) in rest of world markets during 2023 consisted of the following: In January 2024, the company and Eisai announced that the SAG will convene at the request of the CHMP to discuss the MAA of lecanemab that is under review by the EMA. The meeting of the SAG is expected to take place during the first quarter of 2024 and the EC decision for the MAA of lecanemab is expected during the first half of 2024. In January 2024 the NMPA approved LEQEMBI in China, with an expected launch date in 2024. In December 2023, the company and Eisai announced that LEQEMBI intravenous infusion was launched in Japan. In September 2023 the Japanese Ministry of Health, Labor and Welfare approved LEQEMBI in Japan. In January 2023 the EMA accepted for review the MAA for lecanemab. In February 2023 the BLA for lecanemab was granted Priority Review by the NMPA of China. In May 2023, the company and Eisai announced the submission of a MAA for lecanemab to the U.K. MHRA in Great Britain, which has been designated by the MHRA for the Innovative Licensing and Access Pathway. Additionally, in May 2023 Health Canada accepted for review the NDS for lecanemab. In June 2023, the company and Eisai announced the submission of a MAA for lecanemab to the Ministry of Food and Drug Safety in South Korea. ZURZUVAE (zuranolone) In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE for PPD became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. ZURZUVAE for PPD became commercially available in the U.S. during the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. The CRL stated that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies would be needed. The company and Sage are continuing to seek feedback from the FDA and evaluating next steps. Reata Acquisition On September 26, 2023, the company completed the acquisition of all of the issued and outstanding shares of Reata, a biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction the company acquired SKYCLARYS (omaveloxolone), the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. Other Key Developments QALSODY (tofersen) In April 2023, the FDA approved QALSODY for the treatment of ALS in adults who have a mutation in the SOD1 gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). TECFIDERA Following a favorable March 2023 decision of the CJEU affirming TECFIDERA's right to regulatory data and marketing protection and the EC determination in May 2023 that TECFIDERA is entitled to an additional year of market protection for its pediatric indication, the company believe that TECFIDERA is entitled to regulatory marketing protection in the E.U. until at least February 2, 2025, and are seeking to enforce this protection. In December 2023, the EC revoked all centralized marketing authorizations for generic versions of TECFIDERA. As of December 31, 2023, some of the TECFIDERA generics have not yet fully exited some E.U. markets and the company expect removal of all generics from the market will take additional time. The company is closely monitoring this situation and working to enforce the company’s legal right to market protection. In addition, the company will continue to enforce the company’s EP 2 653 873 patent related to TECFIDERA, which expires in 2028. Product and Pipeline Developments Neurology Alzheimer's Disease LEQEMBI (lecanemab) In October 2023, Eisai presented new data for LEQEMBI 100 mg/mL injection for intravenous use at the 2023 CTAD conference. The new data suggests that there is continued benefit associated with LEQEMBI treatment as patients continued to show benefits at 24 months of treatment and after the removal of amyloid plaques. In September 2023, the company and Eisai announced that the LEQEMBI intravenous infusion (200 mg, 500 mg, lecanemab) was approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease. In July 2023, the company and Eisai announced the results of a detailed analysis of the Phase 3 CLARITY Alzheimer's disease study of LEQEMBI at the 2023 AAIC conference. The study provided further Phase 3 analysis showing benefits of LEQEMBI on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer's disease, as well as new data on subcutaneous formulation showing promising PK/PD data modeling on efficacy and safety, representing a potential new option for administering therapy. In March 2023, the company and Eisai announced that three additional detailed analyses from the Phase 2b clinical study (Study 201) of lecanemab, evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease, were published in peer-reviewed journals. BIIB080 In October 2023, the company announced new Phase 1b clinical data from the Phase 1b clinical study of BIIB080, an investigational ASO therapy targeting tau, in mild Alzheimer's disease, showing favorable trends on multiple exploratory endpoints of cognition and activities of daily living in Alzheimer's disease. In October 2023, JAMA Neurology published biomarker data from the placebo-controlled period and long-term extension phase of the BIIB080 Phase 1b study of the ASO which targets tau pre-mRNA in early-stage Alzheimer's disease. This publication includes preliminary data in 46 patients which showed that the investigational therapy substantially reduced soluble and aggregated pathologic tau in patients with mild Alzheimer's disease. In April 2023, Nature Medicine published a manuscript detailing promising results from Biogen's multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target engagement of Biogen's BIIB080. In March 2023, the company presented new data from the Phase 1b clinical study of BIIB080 at the 2023 International Conference on Alzheimer's and Parkinson's Diseases, showing that BIIB080 substantially reduced tau protein levels in patients with early-stage Alzheimer's disease. Rare Disease SPINRAZA (nusinersen) In June 2023, the company announced new data from the Phase 4 RESPOND study, which is designed to evaluate the clinical outcomes and safety following treatment with SPINRAZA in infants and toddlers with SMA who have unmet clinical needs after treatment with ZOLGENSMA (onasemnogene abeparvovec-xioi). Interim results from the Phase 4 RESPOND study showed improved motor function in most participants treated with SPINRAZA after ZOLGENSMA. SKYCLARYS (omaveloxolone) In February 2024, the EC approved SKYCLARYS in the E.U. for the treatment of FA in adults and adolescents aged 16 years and older. SKYCLARYS is the first treatment approved within the E.U. for this rare, genetic, progressive neurodegenerative disease. In December 2023, the CHMP of the EMA issued a positive opinion recommending marketing authorization for omaveloxolone for the treatment of FA in people aged 16 years and older. QALSODY (tofersen) In August 2023, the first Veteran was dosed with QALSODY following the VA's coverage for QALSODY. In July 2023, the European Academy of Neurology guideline recommendations on the management of ALS provided updated guidelines recommending that tofersen be offered as first-line treatment for patients with progressive ALS caused by pathogenic mutations in SOD1. In June 2023, the first patient with SOD1-ALS, outside of a clinical trial or early access program, was dosed with QALSODY. In April 2023, the FDA approved QALSODY for the treatment of ALS in adults who have a mutation in the SOD1 gene. Biosimilars BYOOVIZ (referencing LUCENTIS) In October 2023, BYOOVIZ was granted an interchangeability designation by the FDA and was deemed interchangeable to Genentech's LUCENTIS. In March 2023, the company announced that BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, launched in Canada. In February 2023, Samsung Bioepis announced that BYOOVIZ launched in Germany. TOFIDENCE (referencing ACTEMRA) In September 2023, the FDA approved TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, for the treatment of severe, active and progressive rheumatoid arthritis. Discontinued Programs and Studies Envision Study In November 2023, the company notified Neurimmune of its decision to terminate its collaboration and license agreement with Neurimmune, to discontinue the development and commercialization of ADUHELM and to terminate the ENVISION clinical study. EMBARK Study In September 2023, the company discontinued the company’s EMBARK study for aducanumab. In connection with this discontinuation the company recorded termination costs of approximately $43.0 million in research and development expense within the company’s consolidated statements of income for the year ended December 31, 2023. Acorda Collaboration In January 2024, the company notified Acorda of the company’s decision to terminate its collaboration and license agreement, effective January 1, 2025. As a result of this termination, Acorda will regain global commercialization rights to FAMPYRA. BIIB122 In June 2023, the company and Denali announced plans to terminate the Phase 3 LIGHTHOUSE study for BIIB122, a small molecule inhibitor of LRRK2 in Parkinson's disease. The protocol for the Phase 2b LUMA study for BIIB122 in patients with early-stage Parkinson’s disease was amended to now include eligible patients with a LRRK2 genetic mutation in addition to continuing to enroll eligible patients with early-stage idiopathic Parkinson’s disease. BIIB093 In April 2023, the company would terminate the development of BIIB093 (glibenclamide IV), in a Phase 3 study for LHI and a Phase 2 study for brain contusion, due to operational challenges and other strategic considerations. BIIB131 In April 2023, the company will be pausing the initiation of a Phase 2b study for BIIB131 (TMS-007) for acute ischemic stroke and will continue to assess whether to initiate this study. The company sold the rights to BIIB131 to a third-party biopharmaceutical company. BIIB132 In April 2023, the company would discontinue further development of BIIB132 in spinocerebellar ataxia type 3, as part of the company’s ongoing research and development prioritization initiative. Neurology Multiple Sclerosis The company develops, manufactures and markets a number of products designed to treat patients with MS. Alzheimer's Disease In November 2023, the company notified Neurimmune of its decision to terminate its collaboration and license agreement with Neurimmune and to discontinue the development and commercialization of ADUHELM. Neuropsychiatry Neuropsychiatry includes ZURZUVAE for PPD, which became commercially available in the U.S. during the fourth quarter of 2023. Rare Disease Rare disease includes SPINRAZA for SMA, SKYCLARYS for FA, which was obtained as part of the company’s acquisition of Reata in September 2023 and QALSODY for ALS, which became commercially available in the U.S. during the second quarter of 2023. Biosimilars Biosimilars are a group of biologic medicines that are highly similar to currently available biologic therapies developed by companies known as ‘originators’. Under the company’s agreements with Samsung Bioepis, the company commercializes three anti-TNF biosimilars in certain countries in Europe: BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE. The company has also secured the exclusive rights to commercialize BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, which is commercially available in the U.S. and certain international markets; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which was approved by the FDA during the third quarter of 2023. Genentech Relationships The company has agreements with Genentech that entitle the company to certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, COLUMVI, which was granted accelerated approval by the FDA during the second quarter of 2023, and have the option to add other potential anti-CD20 therapies. Patient Support and Access The company interacts with patients, advocacy organizations and healthcare societies in order to gain insights into unmet needs. The insights gained from these engagements help the company supports patients with services, programs and applications that are designed to help patients lead better lives. Among other things, the company provides customer service and other related programs for its products, such as disease and product specific websites, insurance research services, financial assistance programs and the facilitation of the procurement of the company’s marketed products. The company is dedicated to helping patients obtain access to its therapies. The company’s patient representatives have access to a suite of financial assistance tools. With those tools, the company helps patients understand their insurance coverage, and if needed, helps patients compare insurance options and programs. In the U.S., the company has established programs that provide co-pay assistance or free product for qualified uninsured or underinsured patients, based on specific eligibility criteria. The company also provides charitable contributions to independent charitable organizations that assist patients with out-of-pocket expenses associated with their therapy. The company also works with regulators, clinical researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to the company’s investigational therapies in a manner that is consistent with its patient-focused values and compliant with regulatory standards and protocols. Marketing and Distribution Sales Force and Marketing The company promotes its marketed products worldwide, including in the U.S., Europe and Japan, primarily through the company’s own sales forces and marketing groups. In some countries, particularly in areas where the company continues to expand into new geographic areas, the company partners with third parties. RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and LUNSUMIO are marketed by the Roche Group and its sublicensees. The company commercializes BENEPALI, IMRALDI and FLIXABI pursuant to its agreement with Samsung Bioepis in certain countries in Europe, as well as BYOOVIZ in the U.S. and certain international markets. The company focuses its sales and marketing efforts on physicians in private practice or at major medical centers. The company uses customary industry practices to market its products and to educate physicians. This includes the company’s sales representatives calling on individual health care providers (in-person and virtually), advertisements, professional symposia, direct mail, digital marketing, point of care marketing, public relations and other methods. The company focuses on health care provider sales and marketing efforts on specialty providers in both private practice and at major medical centers. Distribution Arrangements The company distributes its products in the U.S. principally through wholesale and specialty distributors of pharmaceutical products and specialty pharmacies, mail order specialty distributors or shipping service providers. In other countries, the distribution of the company’s products varies from country to country, including through wholesale distributors of pharmaceutical products and third-party distribution partners who are responsible for most marketing and distribution activities. RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and LUNSUMIO are distributed by the Roche Group and its sublicensees. The company distributes BENEPALI, IMRALDI and FLIXABI in certain countries in Europe; and has an option to acquire exclusive rights to distribute these products in China, as well as BYOOVIZ in the U.S. and certain international markets. Competition Neurology Multiple Sclerosis The company’s competitors include Sanofi Genzyme; Banner Life Sciences; Bayer Group; TG Therapeutics, Inc.; Teva Pharmaceuticals Industries Ltd.; Novartis AG; Sandoz, a division of Novartis AG; EMD Serono; Genentech; Janssen Pharmaceutical Companies of Johnson & Johnson; and Bristol Myers Squibb Company. Trademarks ADUHELM, AVONEX, BYOOVIZ, PLEGRIDY, QALSODY, RITUXAN, RITUXAN HYCELA, SKYCLARYS, SPINRAZA, TECFIDERA, TYSABRI and VUMERITY are registered trademarks of Biogen. BENEPALI, FLIXABI, FUMADERM, IMRALDI and TOFIDENCE are trademarks of Biogen. ACTEMRA, COLUMVI, ENBREL, EYLEA, FAMPYRA, GAZYVA, LEQEMBI, HUMIRA, LUCENTIS, LUNSUMIO, OCREVUS, REMICADE, ZURZUVAE and other trademarks are the property of their respective owners. Business Relationships As part of the company’s business strategy, the company establishes business relationships, including entering into licenses, joint ventures and collaborative arrangements with other companies, universities and medical research institutions, to assist in the clinical development and/or commercialization of certain of the company’s products and product candidates and to provide support for the company’s research programs. The company also evaluates opportunities for acquiring products or rights to products and technologies that are complementary to the company’s business from other companies, universities and medical research institutions. EISAI The company has a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. The company manufactures LEQEMBI drug substance and drug product. In March 2022, the company extended its supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance. Sage Therapeutics, Inc. The company has a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD and potential treatment of MDD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions, such as epilepsy. Outside of the U.S., the company is responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. Ionis The company has an exclusive, worldwide option and collaboration agreement with Ionis relating to the development and commercialization of antisense therapeutics for up to three gene targets. Under a separate collaboration and license agreement with Ionis, the company has an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA. The company also has a 10-year exclusive collaboration agreement with Ionis to develop novel ASO drug candidates for a broad range of neurological diseases. In addition, the company has research collaboration agreements with Ionis under which both companies perform discovery level research and will develop and commercialize new ASO drug candidates for the potential treatment of SMA and additional antisense or other therapeutics for the potential treatment of neurological diseases. In December 2018, the company exercised its option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize QALSODY (tofersen), for the treatment of ALS with SOD1 mutations. Genentech The company has agreements with Genentech that entitle the company to certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, COLUMVI, which was granted accelerated approval by the FDA during the second quarter of 2023; and has the option to add other potential anti-CD20 therapies. Denali The company has a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease. Samsung Bioepis The company has an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-TNF biosimilar product candidates in certain countries in Europe and, in the case of BENEPALI, Japan. Under this agreement, the company is commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. In December 2019, the company completed a transaction with Samsung Bioepis and acquired an option to extend the company’s existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in certain countries in Europe. The company has also secured the exclusive rights to commercialize BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, which has been approved in the U.S. and certain international markets, and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which was approved in the U.S. during the third quarter of 2023. In addition to the company’s commercialization agreements with Samsung Bioepis, the company licenses certain of its proprietary technology to Samsung Bioepis in connection with Samsung Bioepis' development, manufacture and commercialization of its biosimilar products. UCB The company has a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Both companies will share equally costs incurred for agreed indications, including research, development, sales and marketing expense. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally. Regulatory The company must adhere to current GMP and product-specific regulations enforced by regulatory agencies following product approval. The company’s products are subject to discounted pricing when purchased by federal agencies via the FSS. FSS participation is required for the company’s products to be covered and reimbursed by the VA, Department of Defense, Coast Guard and PHS. To maintain coverage of the company’s products under the Medicaid Drug Rebate Program and Medicare Part B, the company is required to extend significant discounts to certain covered entities that purchase products under Section 340B of the PHS pharmaceutical pricing program. The company is subject to various federal and state laws pertaining to health care ‘fraud and abuse,’ including anti-kickback laws and false claims laws. The company is subject to various federal and foreign laws that govern its international business practices with respect to payments to government officials. Those laws include the U.S. FCPA, which prohibits the U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. The laws to which the company is subject also include the U.K. Bribery Act 2010 (Bribery Act), which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official and failing to have adequate procedures to prevent employees and other agents from giving bribes. By local ordinance, the company is required to, among other things, comply with the U.S. National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) in relation to the company’s facilities in RTP, North Carolina and are required to operate pursuant to certain permits. Manufacturing Genentech is responsible for all worldwide manufacturing activities for bulk RITUXAN, RITUXAN HYCELA and GAZYVA; and has sourced the manufacture of certain bulk RITUXAN, RITUXAN HYCELA and GAZYVA requirements to a third party. Alkermes supplies both VUMERITY and FAMPYRA to the company pursuant to separate supply agreements. In October 2019, the company entered into a new supply agreement and amended the company’s license and collaboration agreement with Alkermes for VUMERITY. The company has elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party the company has engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by the company or its designee. In January 2023, the company entered into a new supply agreement with Alkermes for FAMPYRA through January 2025. In December 2023, Alkermes entered into a definitive agreement to sell its development and manufacturing facility to Novo Nordisk, which is expected to close in mid-2024. Alkermes and Novo Nordisk plan to enter into subcontracting arrangements to continue work performed at the facility for a period of time after closing the transaction, which may continue through the end of 2025. History The company was founded in 1978. It was formerly known as IDEC Pharmaceuticals Corporation and changed its corporate name to Biogen Idec Inc. in 2003. Further, the company changed its name to Biogen Inc. in 2015.